摘要
目的探讨FUNDC1在非小细胞肺癌中的表达及其对患者临床病理学特征以及预后的影响。方法基于TCGA数据库分析线粒体受体(DRP1、BNIP3、FUNDC1、NIX、RHEB、LC3、OPA1、MFN1)在正常组织与NSCLC组织中表达的差异及其对患者预后的影响。免疫组织化学法检测68例NSCLC以及正常组织中FUNDC1的表达。SPSS22.0统计软件分析FUNDC1表达与患者临床病理特征的相关性及对预后的影响。结果FUNDC1在NSCLC组织中的表达较正常组织明显上调,FUNDC1表达差异与患者区域淋巴结转移和分化程度明显相关(P<0.05),而与患者的年龄、性别、病理分型、远处转移、TNM分期均无相关性,多因素Cox回归分析显示FUNDC1蛋白表达、区域淋巴结转移、病理分化程度可作为非小细胞肺癌患者的独立预后因子。FUNDC1表达的上调与患者总体生存率以及无进展生存率的下降存在明显相关性(P<0.01)。结论FUNDC1的表达上调可影响NSCLC患者的预后,FUNDC1有望成为治疗NSCLC的一个新靶点。
Objective To evaluate the expression of FUNDC1 and its clinical significance in non-small cell lung cancer.Methods We used TCGA database to analyze the difference of mitochondrial receptors(DRP1,BNIP3,FUNDC1,NIX,RHEB,LC3,OPA1 and MFN1)expression between normal and NSCLC tissues,as well as its effect on the prognosis of NSCLC patients.Immunohistochemistry was used to detect FUNDC1 expression.The correlations between FUNDC1 expression and clinicopathological characteristics,prognosis were evaluated by SPSS 22.0 statistical software.Results FUNDC1 expression was increased in NSCLC tissues,compared with normal tissues.FUNDC1 expression was related to the degree of differentiation and lymph node metastasis,but not to gender,age,pathological type,distant metastasis or TNM classification.The Cox regression analysis showed that FUNDC1 protein expression,lymph node metastasis,differentiation degree were independent prognostic factors of NSCLC.Increased FUNDC1 expression was related to decreased OS and PFS(P<0.01).Conclusion The up-regulation of FUNDC1 expression can affect the prognosis of patients with NSCLC.It may be a new potential target for treating with NSCLC.
作者
王玉秀
陈燏
龚道辉
曹柳兆
许文景
徐兴祥
闵凌峰
WANG Yuxiu;Chen Yu;GONG Daohui;CAO Liuzhao;XU Wenjing;XU Xingxiang;MIN Lingfeng(Department of Respiratory and Critical Care Medicine,Northern Jiangsu People’s Hospital,Clinical Medical College of Yangzhou University,Yangzhou 225001,China;Department of Respiratory,Jingjiang People’s Hospital,Jingjiang 214500,China)
出处
《肿瘤防治研究》
CAS
CSCD
2022年第4期322-327,共6页
Cancer Research on Prevention and Treatment
基金
国家自然科学基金(81870033)
江苏省“六大人才高峰计划”(2015-WSN-106)
江苏省医学科学研究基金(QNRC2016340)
扬州市“十三五”高层次人才科研基金(ZDRC201866)
扬州市社会发展科技项目基金(YZ2020070)
江苏省苏北人民医院科研基金(yzucms202001,yzucms201919)。